Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 16
2003 19
2004 15
2005 8
2006 14
2007 8
2008 3
2009 4
2010 4
2011 3
2012 6
2015 1
2016 2
2018 1
2019 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 31644173

101 results

Results by year

Filters applied: . Clear all
Page 1
Drotrecogin alfa.
[No authors listed] [No authors listed] 2018 Jan 8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Jan 8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644173 Free Books & Documents. Review.
Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Bernard GR, et al. N Engl J Med. 2001 Mar 8;344(10):699-709. doi: 10.1056/NEJM200103083441001. N Engl J Med. 2001. PMID: 11236773 Free article. Clinical Trial.
Drotrecogin alfa (activated).
Lyseng-Williamson KA, Perry CM. Lyseng-Williamson KA, et al. Drugs. 2002;62(4):617-30; discussion 631-2. doi: 10.2165/00003495-200262040-00006. Drugs. 2002. PMID: 11893230 Clinical Trial.
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, Dalton HJ, Gessouron MR, Brown KE, Betts H, Levin M, Macias WL, Small DS, Wyss VL, Bates BM, Utterback BG, Giroir BP. Barton P, et al. Pediatrics. 2004 Jan;113(1 Pt 1):7-17. doi: 10.1542/peds.113.1.7. Pediatrics. 2004. PMID: 14702440 Clinical Trial.
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ; Extended Evaluation of Recombinant Human Activated Protein C United States Investigators. Bernard GR, et al. Chest. 2004 Jun;125(6):2206-16. doi: 10.1378/chest.125.6.2206. Chest. 2004. PMID: 15189943 Clinical Trial.
101 results